SCHEMBL5872819

SCHEMBL5872819

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)N2CCN(c3nc4ccccc4s3)CC2)c(F)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
STAT3 P40763 1/20 0.48
NAAA Q02083 5/20 0.46
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALOX15 P16050 2/20 0.44
HTT P42858 2/20 0.44
TSHR P16473 2/20 0.44
CASP1 P29466 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 6/20 0.44
RAB9A P51151 5/20 0.44
TP53 P04637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872839 0.87 MAP2K1 (0.42) MAPTMEN1KMT2ATDP1
SCHEMBL5872892 0.85 MAP2K2 (0.41) ALDH1A1SMN1; SMN2HTTTSHRCASP1
SCHEMBL5872837 0.83 HCAR2 (0.49) LMNANAAASMN1; SMN2HTTTSHR
SCHEMBL5872785 0.82 MAP2K1 (0.40) MEN1KMT2ATDP1
SCHEMBL5872805 0.81 ALDH1A1 (0.51) LMNAMAPTALDH1A1SMN1; SMN2TSHR
SCHEMBL5872955 0.81 MAP2K1 (0.42) ALDH1A1MEN1KMT2ATDP1
SCHEMBL5872799 0.80 MAP2K1 (0.49) MEN1KMT2AMAPK1TDP1
SCHEMBL5872787 0.79 MAP2K1 (0.42) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL5872944 0.79 MAP2K1 (0.43) MEN1KMT2AMAPK1TDP1
SCHEMBL5872945 0.79 MAP2K1 (0.43) MEN1KMT2AMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 LMNA 2398/4885STAT3 1123/4885NAAA 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.